Discussion To our knowledge, this is the first real-world-study-based CEA of using GLP-1RAs versus insulin for T2D patients who require a greater glucose-lowering effect of injection therapy, and the first systematic review on this topic
I see people arguing that because we have not seen a clear increase in aspiration events, there is no need to treat these patients differently
The good news is that sulfur burps on GLP-1 medications are well understood, usually temporary, and highly treatable once you know what is actually causing them
GLP-1 is known to modulate inflammation
The basics still matter most
Phentermine is a Schedule IV controlled substance requires DEA registration, PDMP database checks in most states, subject to Ryan Haight Act rules (currently waived federally through 2026), and some states have additional restrictions on teleprescribing